0.00Open0.10Pre Close0 Volume10 Open Interest22.00Strike Price0.00Turnover595.76%IV96.10%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0613Delta0.0279Gamma112.70Leverage Ratio-0.0984Theta0.0000Rho6.91Eff Leverage0.0009Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet